Research That Matters – Long-Acting Injectable Buprenorphine for Opioid Use Disorder
This six-month observational study of 227 patients with moderate to severe opioid use disorder demonstrated that monthly injectable extended-release buprenorphine significantly improved treatment adherence, reduced opioid use, and lowered healthcare utilization compared to baseline. Patients experienced:
- a 60% reduction in opioid use
- 40% fewer emergency department visits
- 35% fewer hospitalizations
- high satisfaction and improved quality of life.
By eliminating the need for daily dosing, long-acting buprenorphine addressed common adherence challenges and showed strong potential to support sustained recovery while reducing healthcare system burden, reinforcing the value of expanded access and payer coverage for long-acting MOUD options.
Want To Read More?
This content is exclusive to RECADEMY members.
RECADEMY is a comprehensive, research-based, online learning collaborative designed to provide critical information about emerging substance use disorder treatment topics and models of care.
Sign in or join the RECADEMY community for free today.
